3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
54
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma
4
Neoplasm Metastasis
4
Sarcoma, Ewing
3
Neoplasms
3
Medulloblastoma
3
Lymphoma, Non-Hodgkin
3
Glioma
3
Carcinoma, Non-Small-Cell Lung
3
Astrocytoma
3
Wilms Tumor
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Osteosarcoma
2
Oligodendroglioma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Lymphoma
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioblastoma
2
Ependymoma
2
Colonic Neoplasms
2
Xanthogranuloma, Juvenile
1
Triple Negative Breast Neoplasms
1
Testicular Neoplasms
1
Teratoma
1
Recurrent Squamous Cell Lung Carcinoma
1
Interventions
pembrolizumab
37
Paclitaxel
36
Carboplatin
31
Cyclophosphamide
22
Albumin-Bound Paclitaxel
20
atezolizumab
16
130-nm albumin-bound paclitaxel
16
Taxes
15
Doxorubicin
15
Cisplatin
13
Capecitabine
13
Nivolumab
10
Docetaxel
8
olaparib
7
Gemcitabine
6
Everolimus
6
talazoparib
5
durvalumab
5
Magnetic Resonance Spectroscopy
5
Biopsy
5
Bevacizumab
5
veliparib
4
spartalizumab
4
sacituzumab govitecan
4
pegfilgrastim
4
liposomal doxorubicin
4
eribulin
4
Specimen Handling
4
Immunoglobulin G
4
trilaciclib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Triple Negative Breast Neoplasms
×
palbociclib
×
Clear all
NCT04494958
2025-03-24
PALBOBIN
Fundacion Oncosur
Phase 1/2
Completed
24 enrolled
10 charts